[{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma announces positive topline results from Phase 2 trial with dasiglucagon","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces FDA Acceptance of NDA for the Dasiglucagon Hypopal rescue Pen for Treatment of Severe Hypoglycemia","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Presents Clinical and Non-Clinical Evidence for Dasiglucagon Rescue Therapy","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"DEKA Research & Development","sponsor":"Zealand Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism (CHI)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"$100.0 million","newsHeadline":"Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces FDA Approval of Zegalogue injection, for the Treatment of Severe Hypoglycemia in People with Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Receives First FDA Approval and Prepares for Launch of Zegalogue (Dasiglucagon) Injection","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma Announces Directed Issue and Private Placement Corresponding to Approx. 6.6 % of Existing Share Capital","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$39.2 million","upfrontCash":"$3.4 million","newsHeadline":"Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE\u00ae (dasiglucagon)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","amount":"$218.9 million","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma Announces Completion Of A Directed Issue And Private Placement Of 6,578,948 Million New Ordinary Shares Raising Gross Proceeds Of DKK 1.5 Billion","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank A\/S","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zealand Pharma Announces Directed Issue And Private Placement Of Approximately 6.5 Million New Shares","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma Submits New Drug Application to US FDA for Dasiglucagon in Congenital Hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II\/ Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Declines to Approve Zealand Pharma's Drug for Low Blood Sugar in Infants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Peptide","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals for Dasiglucagon
ZP4207 (dasiglucagon) is a glucagon receptor agonist, peptide drug candidate, which is currently being evaluated for the treatment of congenital hyperinsulinism.
ZP4207 (dasiglucagon) is being investigated by Zealand Pharma for subcutaneous continuous infusion using a wearable pump system as a potential treatment of congenital hyperinsulinism in pediatric patients 7 days of age and older.
ZP4207 (dasiglucagon) subcutaneous injection is a glucagon receptor agonist and indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Zegalogue (dasiglucagon) subcutaneous injection is a glucagon receptor agonist and indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
The net proceeds will be used for supporting the late stage rare disease assets, including Zegalogue (dasiglucagon), a glucagon analog that acts to increase blood sugar levels, being developed for the treatment of congenital hyperinsulinism.
The net proceeds will be used for supporting the late stage rare disease assets, including Zegalogue (dasiglucagon), a glucagon analog that acts to increase blood sugar levels, being developed for the treatment of congenital hyperinsulinism.
Dasiglucagon (ZP4207) is a glucagon analog that is stable in aqueous solution and is thus suitable for administration via chronic subcutaneous infusion via pump.Phase 3 study demonstrates that dasiglucagon treatment resulted in a significant reduction in glucose infusion rate.
Under the terms of the agreement, Zealand will be responsible for certain planned development, regulatory, and manufacturing activities of Zegalogue (dasiglucagon) to support approval outside the U.S.
The net proceeds from the Private Placement are expected to be used to strengthen Zealand’s ability to execute on the refocused strategy prioritizing R&D and entering partnerships for commercial and late-stage development products.
ZP4207 (dasiglucagon) met the primary endpoint with statistical significance - reducing the requirement for intravenous glucose by 55% compared to placebo in this pediatric patient population (ages 7 days to 12 months) when compared to placebo.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
